RET and thyroid gland carcinoma: Vandetanib and lenvatinib, which are FDA-approved RET kinase inhibitors with clinical efficacy against RET fusion-positive thyroid cancer [14, 15], followed the same pattern and specifically inhibited only Lc2/ad cells viability (Figure 2C and 2D).